• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION REZUM; UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION REZUM; UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES) Back to Search Results
Model Number D2201
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Hemorrhage/Bleeding (1888); Inflammation (1932); Pain (1994); Complaint, Ill-Defined (2331)
Event Date 01/31/2020
Event Type  Injury  
Event Description
It was reported that this patient underwent convective radiofrequency water vapor thermal therapy procedure of the prostate on (b)(6) 2020 using the delivery device.Prior to the procedure the patients prostate specific antigen (psa) results and palpation of the prostate were not considered a concern.In (b)(6) 2020, the patient experienced heavy bleeding following sexual activity that lasted for 11 days as well as pain in the prostate area.In (b)(6) 2020, there was prostate inflammation.The patient is taking the prescribed medication but experienced tissue detachment at the end of (b)(6) 2020.The patients urinary stream is also weak and split.The urologist suspects there is residual tissue present and is considering performing a peeling procedure at a later date.No additional adverse patient effects were reported; however, the patients urinary stream is becoming weaker and the patient is concerned about prostate cancer.At this time, no further information on this event has been reported.
 
Manufacturer Narrative
The device is not available for analysis.A review of the ifu and operators manual was completed and did not reveal any evidence of device misuse, off-label use, or failure to follow instructions.Based on review of the information available, hemorrhage, pain and inflammation are known risk associated with the use of the device and is noted as such in the instruction for use (ifu).An evaluation conclusion code of known inherent risk of the device was assigned to this investigation.
 
Event Description
It was reported that the patient underwent convective radiofrequency water vapor thermal therapy procedure of the prostate on (b)(6) 2020, using the delivery device.Prior to the procedure the patient prostate specific antigen (psa) results and palpation of the prostate were not considered a concern.In (b)(6) 2020, the patient experienced heavy bleeding following sexual activity that lasted for 11 days as well as pain in the prostate area.In (b)(6) 2020, there was prostate inflammation.The patient is taking the prescribed medication but experienced tissue detachment at the end of (b)(6) 2020.The patient urinary stream is also weak and split.The urologist suspects there is residual tissue present and is considering performing a peeling procedure at a later date.No additional adverse patient effects were reported; however, the patient urinary stream is becoming weaker and the patient is concerned about prostate cancer.At this time, no further information on this event has been reported.
 
Event Description
It was reported that the patient underwent convective radiofrequency water vapor thermal therapy procedure of the prostate on (b)(6) 2020 using the delivery device.Prior to the procedure the patient's prostate specific antigen (psa) results and palpation of the prostate were not considered a concern.In (b)(6) 2020 the patient experienced heavy bleeding following sexual activity that lasted for 11 days as well as pain in the prostate area.In (b)(6) 2020 there was prostate inflammation.The patient is taking the prescribed medication but experienced tissue detachment at the end of (b)(6) 2020.The patients urinary stream is also weak and split.The urologist suspects there is residual tissue present and is considering performing a peeling procedure at a later date.No additional adverse patient effects were reported; however, the patient's urinary stream is becoming weaker and the patient is concerned about prostate cancer.At this time, no further information on this event has been reported.
 
Manufacturer Narrative
B1 adverse event/product problem field corrected.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
REZUM
Type of Device
UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES)
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
MDR Report Key10603970
MDR Text Key209134342
Report Number2937094-2020-00845
Device Sequence Number1
Product Code KNS
Combination Product (y/n)N
PMA/PMN Number
K180237
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup,Followup
Report Date 12/18/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date09/30/2021
Device Model NumberD2201
Device Catalogue NumberD2201
Device Lot Number2019091037
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 09/04/2020
Initial Date FDA Received09/29/2020
Supplement Dates Manufacturer Received10/15/2020
12/15/2020
Supplement Dates FDA Received11/05/2020
12/18/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other;
-
-